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Aims: Schizophrenia is associated with cardiovascular co-morbidity and a reduced life-
expectancy of up to 20 years. Antipsychotics are dopamine D2 receptor antagonists and are
the standard of medical care in schizophrenia, but the drugs are associated with severe meta-
bolic side effects such as obesity and diabetes. Glucagon-like peptide-1 receptor agonists
(GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes. We investigated
metabolic effects of the GLP-1RA, exenatide once-weekly, in non-diabetic, antipsychotic-trea-
ted, obese patients with schizophrenia.
Material and methods: Antipsychotic-treated, obese, non-diabetic, schizophrenia spectrum
patients were randomized to double-blinded adjunctive treatment with once-weekly subcuta-
neous exenatide (n = 23) or placebo (n = 22) injections for 3 months. The primary outcome
was loss of body weight after treatment and repeated measures analysis of variance was used
as statistical analysis.
Results: Between March 2013 and June 2015, 40 patients completed the trial. At baseline,
mean body weight was 118.3  16.0 kg in the exenatide group and 111.7  18.0 kg in the
placebo group, with no group differences (P = .23). The exenatide and placebo groups experi-
enced signiﬁcant (P = .004), however similar (P = .98), weight losses of 2.24  3.3 and
2.23  4.4 kg, respectively, after 3 months of treatment.
Conclusions: Treatment with exenatide once-weekly did not promote weight loss in obese,
antipsychotic-treated patients with schizophrenia compared to placebo. Our results could sug-
gest that the body weight-lowering effect of GLP-1RAs involves dopaminergic signaling, but
blockade of other receptor systems may also play a role. Nevertheless, anti-obesity regimens
effective in the general population may not be readily implemented in antipsychotic-treated
patients with schizophrenia.
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1 | INTRODUCTION
Schizophrenia is a severe mental illness affecting approximately .5%
of the world’s population.1 Patients with schizophrenia have a 2- to
3-fold increased risk of premature death, mainly resulting from cardi-
ovascular diseases2 and, consequently, a reduced life expectancy of
up to 20 years compared to the background population.1,3 With the
increasing use of so-called second generation antipsychotics, the
mortality gap between patients with schizophrenia and the back-
ground population appears to be expanding.4
Obesity is considered the single most important risk factor for
development of diabetes and cardiovascular diseases. The prevalence
of obesity (body mass index (BMI) ≥ 30 kg/m2) in the USA has been
estimated as 60% in patients with schizophrenia compared to approx-
imately 30% in the background population.5,6 The etiology of obesity
is multifactorial and inﬂuenced by, eg, genetic predisposition, physical
inactivity and unhealthy dietary habits.7 In patients with severe men-
tal illness, treatment with antipsychotics is an additional contributor
to obesity.2,4
The mechanisms underlying the association between antipsycho-
tics and obesity are not fully understood. Notably, all marketed
antipsychotics share the mechanism of dopamine D2 receptor antag-
onism.8 Dopamine is the main modulator of the brain’s reward
system, and dopaminergic signaling is pivotal in the regulation of
appetite and food intake,9,10 and central insulin-receptors may also
modulate striatal dopamine release.11 Recently, we reported that
attenuated brain reward activity in antipsychotic-naïve patients with
schizophrenia was associated with individual susceptibility to gain
weight prior to antipsychotic exposure.12 Moreover, brain activity
after dopamine D2 receptor antagonism was associated with weight
gain after treatment.12 Antipsychotics are effective in reducing psy-
chotic symptoms; hence, clinical and ethical imperatives to alleviate
these symptoms render antipsychotics, despite their severe metabolic
side effects, the standard of medical care in schizophrenia and other
psychotic disorders.13
Current strategies to reduce antipsychotic-associated weight gain
and obesity include antipsychotic dose reduction, change of antipsy-
chotic compound, behavioral therapy including diet and exercise
interventions, psychotherapy and add-on pharmacological therapy, eg
metformin. These regimens may result in up to 4 kg-reductions in
body weight, but sustainability is questionable, and clear recommen-
dations are not available.14–18
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) constitute
an antidiabetic and antiobesity drug class that mimicks the effects of
the endogenous gut hormone GLP-1. GLP-1 regulates blood glucose
homeostasis and appetite through peripheral and central actions. In
addition to the blood glucose- and body weight-lowering effects of
GLP-1RAs, these drugs moderately reduce blood pressure and blood
lipids.19 The side effects of the GLP-1RAs are generally tolerable,
mostly comprising temporary, mild-to-moderate gastrointestinal
symptoms (nausea, vomiting and diarrhea).19
Based on these favourable features, we previously proposed
GLP-1RAs as a potential body weight-lowering treatment for obese
patients with schizophrenia.20,21 Here we report results from the ﬁrst
randomized trial investigating the effect of a GLP-1RA on body
weight in patients with schizophrenia and antipsychotic-associated
obesity. As secondary outcomes, we report effects on blood pressure,
pulse rate, body composition and biochemical parameters.
2 | MATERIALS AND METHODS
2.1 | Study setting and design
The study was an investigator-initiated, randomized, placebo-con-
trolled, double-blinded, parallel group, 3-month intervention trial. The
trial protocol has been published previously.22 In short, antipsychotic-
treated, clinically stable schizophrenia spectrum patients (ICD-10
diagnoses F20.x and F25.x) between 18 and 65 years of age with
obesity were recruited from psychiatric clinics in the capital region of
Copenhagen, Denmark. Exclusion criteria included diabetes, current
substance dependency and pregnancy. Baseline examinations (week
0) were followed by a weekly injection of trial medication (12-16
injections per participant) and 3 scheduled visits: at 1 week (7  2
days), at 4 weeks (4-6 weeks) and at end-of-trial (12-6 weeks). A
CONSORT-ﬂowchart of the study is provided in Figure 1.23
2.2 | Randomization and blinding
The randomization code was a computer-generated randomization
allocation sequence with a block size of initially 40 and subsequently
10 to reach the goal of 40 patients completing the trial (20 in each
group). Allocation ratio was 1:1. Using the randomization code,
16 sealed allocation envelopes, one per week, were prepared and
validated for each patient. For each injection, the staff responsible
for administering medication collected the relevant envelope from a
locked cabinet, not accessible to the principal investigator (PLI). To
maintain blinding during administration of trial medication to patients,
injection pens were prepared and covered with opaque labels in a
separate room. Blinding was kept until analyses on the primary end-
point had been performed.24
2.3 | Approvals and ethics
The study was approved by the National Committee on Health
Research Ethics (project no.: 36378), the Danish Health and Medi-
cines Authority (EudraCT no.: 2012-005404-17) and The Danish Data
Protection Agency (project no.: RHP-2012-027) and was conducted
according to the Declaration of Helsinki II (7th revision, 2013). The
Good Clinical Practice (GCP) Unit at Copenhagen University Hospital
monitored the trial according to ICH-GCP guidelines. All referrals
received an oral and written description of the trial and were
screened by the principal investigator. All patients approved partici-
pation by written informed consent prior to enrolment.
2.4 | Trial medication
Trial medication was the GLP-1RA exenatide once-weekly (Bydureon,
AstraZeneca AB, Södertälje, Sweden). The once-weekly administra-
tion proﬁle of Bydureon was judged favourable for facilitating trial
adherence in our psychiatric patient sample. A subcutaneous injection
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with either exenatide 2 mg (ﬁxed dose) or placebo once-weekly, was
administered by unblinded trial personnel as described above. Pla-
cebo injections were solvent from the Bydureon kit (without exena-
tide). Tolerability was evaluated by giving the ﬁrst two injections at
the psychiatric research facility. Full medication compliance was
ensured by giving all subsequent injections in the home of the
patient. Adverse events were recorded at trial visits.
2.5 | Primary outcome
The primary outcome was loss of body weight after 3 months of
treatment with exenatide once-weekly compared to placebo. Patients
received no instructions on diet and exercise during the trial. Our
power calculation was based on an expected difference in weight loss
of 2.5  2.5 kg in the exenatide group vs 0  2.5 kg in the placebo
group, and showed that, to reach a power of 0.8, a sample size of
16 patients in each group was needed.22 Patients were weighed at all
4 scheduled visits. Body weight measurement was obtained without
shoes and coat, using an authorized and calibrated scale, Cardinal
Detecto 750 (Webb City, Missouri).
2.6 | Secondary outcomes
2.6.1 | Waist and hip circumference measurements
At all visits, waist circumference was measured with the patient in
a standing position and the measure tape positioned horizontally
at the level of the iliac crest. To measure hip circumference, the
measure tape was positioned horizontally at the widest point of
the hip.
2.6.2 | 24-hour blood pressure measurement
At baseline and end-of-trial, we performed a 24-hour (24 h) blood
pressure recording with approximately 80 measurements, using the
validated monitor, Mobil-O-Graph 24 hour PWA Monitor (I.E.M.
GmbH, Stolberg, Germany).25 Here we report data on central (systolic
and diastolic), peripheral (systolic and diastolic) blood pressures, pulse
rate and aortic pulse wave velocity for arterial stiffness quantiﬁca-
tion.26 Quality and validity of the measurements were determined by
the Mobil-O-Graph.
2.6.3 | Dual-energy X-ray absorptiometry (DEXA)
To assess changes in body composition from baseline to end-of-trial,
patients underwent a whole-body DEXA scan in the fasting state
using the Lunar Prodigy whole-body scanner (General Electric Medi-
cal Systems, Madison, Wisconsin) in conjunction with the software
enCORE version 14.1. Data on visceral adipose tissue, body fat per-
centage, muscle-mass and android-to-gynoid fat mass ratio are
reported.
2.6.4 | Blood sampling
Blood sampling was performed in the fasting state at baseline, at
4 weeks and at end-of-trial visits and analysis was by the Department
of Clinical Biochemistry, Rigshospitalet, University of Copenhagen
(Glostrup, Denmark) using standard methods. We report on glycated
hemoglobin A1c (HbA1c), an indicator of long-term blood glucose
levels (a value <42 mmol/mol indicates normoglycemia), fasting blood
glucose and lipids (Table 3).
2.6.5 | Experimental procedures regarding exenatide, anti-
exenatide antibodies and glucagon
Plasma samples intended for analyses for exenatide, anti-exenatide
antibodies and glucagon were stored at −80C as previously
described.27,28 The sensitivity of the exenatide assay is <1 pmol/L,
but in order to avoid plasma interference, samples were diluted 10-
fold in assay buffer. For estimation of antibodies against exenatide,
plasma samples were incubated with 125-I-labelled exendin 9-39,
which binds to the antiserum with same energy as full-length exena-
tide, and tracer-antibody complexes separated from the mixture using
plasma-coated charcoal as in the exenatide radioimmunoassay. Any
increases in binding of the tracer, above that observed in plasma from
Assessed for eligibility (n=65) 
Excluded (n=20) 
• Not meeting inclusion criteria (n=7) 
• Declined to participate (n=8) 
• Other reasons (e.g. not reachable by   
telephone (n=5)) 
Analysed with regards to primary outcome
(n=20) 
Discontinued intervention (n=3)
Two due to gastro-intestinal side effects  
Allocated to exenatide once-weekly (n=23)
Discontinued intervention (n=2)
One due to dizziness 
One due to psychotic deterioration  
Allocated to placebo (n=22)
Analysed with regards to primary outcome
(n=20)
Randomized (n=45)
End-of-trial
One due to lack of weight loss
FIGURE 1 Study diagram of the patient ﬂow
according to CONSORT 2010 statement. Of the
65 patients originally referred to the study,
45 entered the subsequent 3-month treatment
period. Five patients withdrew from trial, resulting
in a completion of n = 40 (n = 20 exenatide only
weekly, n = 20 placebo).
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subjects never exposed to exenatide, is indicative of the presence of
antibodies and results are presented in percent binding of the tracer,
a proxy of antibody titer. The glucagon assay employs a C-terminally
directed antiserum and therefore measures glucagon of mainly pan-
creatic origin. Sensitivity was <1 pmol/L.
2.7 | Statistical methods
Data analyses on the primary outcome and most of the secondary
outcomes were performed before un-blinding and according to the
per-protocol principle. Analyses of adverse events were performed
according to the intention-to-treat principle, including data from
drop-outs (n = 45) (Figure 1). Demographic variables and clinical char-
acteristics are reported in frequency (percentage) for categorical data,
and in mean values (with standard deviations and range) for normally
distributed, continuous variables. Group comparisons for demo-
graphic data were performed using independent t-tests for continu-
ous variables and Chi-square tests for nominal and ordinal variables.
Primary and secondary outcomes were tested using rmANOVA. The
between-subject factor, ie exenatide vs placebo, was denoted
“Group,” and the within-subject factor between time points was
denoted “Time.” A signiﬁcant “Time × Group interaction” indicates a
difference in response between the two treatment groups. Because
of the exploratory nature of the analyses of secondary outcomes, we
did not correct for multiple comparisons. All statistical tests were
two-tailed and .05 was set as the signiﬁcance level throughout. IBM
SPSS version 23 (IBM Corporation, Armonk, New York) was used for
statistical analyses.
3 | RESULTS
Between March 2013 and June 2015, a total of 65 subjects were
referred to the trial. Among 65 patients, 57 were outpatients (87.7%).
A total of 20 referrals met exclusion criteria (Figure 1). A total of
45 patients were enrolled in the trial and randomized to treatment
with either exenatide or placebo and 5 patients dropped out, corre-
sponding to an attrition rate of 11%. In the exenatide group,
3 patients dropped out, 2 because of intolerable gastrointestinal side
effects and 1 because of dissatisfaction with the clinical effect, ie
unchanged body weight after 9 weeks of treatment. In the placebo
group, 1 patient dropped out because of severe nausea and dizziness
and 1 because of worsening of psychotic symptoms. A total of 40
patients (20 in each group) completed the trial (Figure 1). Over the
3-month intervention period the mean number of injections ( stand-
ard deviation [SD]) was 14.2  1.0 in the exenatide group and
14.2  1.2 in the placebo group (P = .89).
At baseline, we found no signiﬁcant differences between groups
concerning age, gender, ethnicity, socio-economic status, lifetime drug
dependency, diagnosis, weight, height, BMI or HbA1c (P values > .23)
(Table 1). In the exenatide group, 7 patients were smokers compared
to 1 patient in the placebo group (P = .02) (Table 1).
Patients were treated with various antipsychotics in both groups
(both monotherapy and polypharmacy), including ﬁrst generation anti-
psychotics (perphenazine, zuclopenthixol and chlorprothixene) and
second generation antipsychotics (clozapine, olanzapine, aripiprazole,
risperidone, paliperidone, quetiapine, ziprasidone, amisulpride and ser-
tindole) with no differences between groups (P values > .35) (Table 1).
TABLE 1 Demographics and baseline characteristics of patients
Exenatide (n = 20) Placebo (n = 20)
Mean SD Range Mean SD Range P value
Age (years) 37.4 10.7 19-65 34.4 10.6 19-56 .37
Gender (male/female) 11/9 9/11 .53
Ethnicity (%)
Caucasian 47.5 45.0 .55
Mongolian 2.5 5.0
Education (years) 12.2 2.6 12.2 2.7 .93
Smoking yes/no (%) 7/13 (35) 1/19 (5) .02*
Lifetime substance dependency yes/no (%) 7/13 (35) 4/16 (20) .45
Diagnosis (%)
Schizophrenia, F20.x 90 90 N/A
Schizoaffective, F25.x 10 10 N/A
Body weight (kg) 118.3 16.0 84.4-150.7 111.7 18.0 88.2-149.7 .23
Height (cm) 172.8 8.4 162-192 170.4 10.1 153-190 .42
BMI (kg/m2) 39.5 3.5 31.0-48 38.6 6.3 30.1-55.1 .54
HbA1c (mmol/mol) 33.3 3.3 28-40 34.7 4.8 25-47 .31
Typical antipsychotic monotherapy (%) 5 (n = 1) 5 (n = 1) 1
Atypical antipsychotic monotherapy (%) 60 (n = 12) 45 (n = 9) .36
Antipsychotic polypharmacy (%) 35 (n = 7) 50 (n = 10) .35
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c (<42 mmol/mol indicates normoglycemia; 42-47 mmol/mol indicates prediabetes and
>48 mmol/mol indicates diabetes); N/A, not applicable.
Mean, standard deviation (SD) and range are presented in the table. Group differences were tested by independent two-sample t-test and Chi square
tests, and signiﬁcant group differences are indicated by asterisks (*).
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3.1 | Primary outcome
At baseline, mean body weight in the exenatide group was
118.3  16.0 kg vs 111.7  18.0 kg in the placebo group, with no
differences between groups (P = .23). During the intervention, the
exenatide and placebo groups experienced similar reductions in body
weight (2.2  3.3 and 2.2  4.4 kg, respectively) (Figure 2). This
effect on body weight was signiﬁcant (P = .004), without effect of
Group (P = .25) or a Time × Group interaction (P = .98) (Table 2).
Accordingly, the mean BMI decreased signiﬁcantly (P = .004) in both
groups from 39.5  3.5 to 38.7  3.7 kg/m2 in the exenatide group
and from 38.6  6.3 to 37.8  6.7 kg/m2 in the placebo group, with
no Group differences (P = .64) and no Time × Group interaction
(P = .97). Intention-to-treat analysis on primary outcome showed sim-
ilar results; the effect of Time on body weight was signiﬁcant
(P = .004), and no effect of Group (P = .22) or Time × Group interac-
tion were found (P = .98). Post hoc correction for smoking status did
not signiﬁcantly change our result concerning the primary outcome.
Post hoc analysis concerning change in body weight scores, with
baseline body weight as covariate, was also insigniﬁcant (P = .87).
3.2 | Secondary outcomes
Plasma exenatide signiﬁcantly increased in the exenatide group com-
pared to the placebo group (P = .002) (Table 3). Exenatide treatment
compared to placebo (Time × Group interaction) signiﬁcantly reduced
central 24-hour systolic blood pressure (P = .004) and pulse wave
velocity (P = .007).
Signiﬁcant effects of Time were found on central 24-hour sys-
tolic blood pressure (P = .05), peripheral 24-hour systolic blood pres-
sure (P = .03), HbA1c (P = .001), fasting plasma glucose (P = .002),
plasma exenatide (P = .002), triglyceride (P < .001), total cholesterol
(P < .001), low-density lipoprotein (P < .001), very low-density lipo-
protein (P < .001) and high-density lipoprotein cholesterol (P < .001).
Regarding plasma exenatide, we found an effect of Group (P < .001),
but no effect of Group was found for any other secondary outcomes
(P > .06). Post hoc correction for smoking status did not signiﬁcantly
change results concerning any secondary outcomes.
Among 20 patients treated with exenatide, 13 developed signiﬁ-
cant binding of labeled exendin, ie anti-exenatide antibodies, com-
pared to none in the placebo group (P = .004). Post hoc analyses
excluding these 13 patients did not signiﬁcantly alter conclusions per-
taining to the primary outcome (P = .47) or any of the secondary out-
comes. Plasma concentrations of exenatide are reported only for
subjects without concomitant measurable antibodies (4 weeks,
n = 13 and end-of-trial, n = 7). Two to ﬁve Mobil-O-Graph 24-hour
PWA Monitor parameter measurements were of poor quality and
were excluded from statistical analyses (Table 2). Correction for age,
mean arterial pressure (MAP) at baseline, and delta MAP (MAP end-
of- trial minus MAP baseline) did not remove the signiﬁcant Time ×
Group interaction for pulse wave velocity (P = .02). Because of inva-
lid or missing measurements from DEXA scans, the numbers of ana-
lysed measurements are less than 20. Mean values for secondary
outcome measures are provided in Tables 2 and 3.
3.3 | Adverse events
The exenatide group reported more diarrhea (n = 5, 21.7%; P = .02)
and fatigue (n = 4, 17.4%; P = .04) compared to 0% in the placebo
group (Table 4). No other differences in adverse events were
observed (P values > 0.16).
A total of 6 serious adverse events were registered during the
trial, but none were regarded as related to trial medication. In the
exenatide group, 2 patients were admitted to a somatic hospital
during participation. One patient had known intermittent suicidal
behavior and was admitted following a suicide attempt with aceta-
minophen. One patient was admitted because of exacerbation of
known irritable bowel syndrome resulting in dehydration and an unin-
tended lithium-intoxication. In the placebo group, 4 patients were
admitted to somatic hospital during participation, 2 patients because
of pneumonia, 1 patient because of acute dizziness (assumed to rep-
resent benign paroxysmal positional vertigo) and 1 patient because of
the onset of type 2 diabetes (this patient was hospitalized for 4 days,
received insulin and metformin and completed the trial).
4 | DISCUSSION
This is the ﬁrst report on GLP-1RA effects on body weight and other
metabolic and physiological outcomes in obese schizophrenia
patients. With reductions in body weight of approximately 2.3 kg in
both the exenatide and placebo-treated groups, a body weight-
lowering effect of exenatide once-weekly could not be identiﬁed
after 3 months of treatment. This ﬁnding was surprising, as previous
placebo-controlled trials with GLP-1RAs in obese diabetic, as well as
obese non-diabetic, non-psychiatric patients, have consistently
reported body weight losses.29 Speciﬁcally, 2 mg exenatide once-
FIGURE 2 Time lines of mean body mass index (BMI) over a 3-
month period after glucagon-like peptide-1 receptor agonist (GLP-
1RA) treatment in obese patients with schizophrenia. Blue line:
exenatide group; red line: placebo group. Repeated measures analysis
of variance showed no treatment effect of exenatide treatment,
Time × Group interaction (P = .98). The x-axis shows time points for
body weight measurements. Horizontal lines on these time points are
BMI standard deviations within the groups.
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weekly for 3 months resulted in weight loss of approximately 3 kg
compared to placebo in several clinical studies in obese type 2 diabe-
tic individuals.30,31
In diabetic and non-diabetic populations with obesity, treatment
duration and dose of GLP-1RA are positively correlated to a body
weight-lowering effect.29 Both the dose of exenatide and duration of
treatment may have affected the outcome of our trial; however, as
the most prominent weight loss normally is achieved within the ﬁrst
16 weeks of treatment, we consider duration of treatment here to be
adequate.32 For saxenda (the GLP-1RA liraglutide for obesity) the lira-
glutide dose (3 mg once-daily) is almost 2-fold the antidiabetic dose
of liraglutide in victoza (up to 1.8 mg once-daily), and discontinuation
TABLE 2 Results on primary and secondary outcomes after 3 months of treatment
Exenatide (n = 20) Placebo (n = 20)
Time Group Time × Group
Baseline End-of-trial Baseline End-of-trial P value P value P value
Body weight (kg) 118.3  16.0 116.0  16.9 111.7  18.0 109.1  19 .004* .25 .98
[84.4-150.7] [82.2-151.9] [88.2-149.7] [82.6-145.9]
BMI (kg/m2) 39.5  3.5 38.7  3.7 38.6  6.3 37.8  6.7 .004* .64 .97
[31-48] [30.2-47.9] [30.1-55.1] [28.6-55.11]
Waist circumference (cm) 128.4  11.1 127.7  12.1 125.3  13.5 124.4  14.9 .33 .56 .48
[106-150] [101-149] [105-150] [100-149]
Hip circumference (cm) 124.0  8.6 122  9.3 118.5  13.4 118.1  14.8 .21 .23 .42
[110-147] [110-146] [98-152] [96-153]
Central 24 h systolic blood pressure (mm Hg) 122.4  14.6 115.6  13.0 110.5  8.9 111.9  10.1 .048* .06 .004*
[100-143] [95-140] [97-141] [94-132]
n = 15 n = 15 n = 16 n = 16
Central 24 h diastolic blood pressure
(mm Hg)
83.7  12.4 81.6  11.4 78.1  9.5 78.6  8.9 .48 .24 .26
[65-107] [63-101] [67-96] [63-96]
n = 15 n = 15 n = 16 n = 16
24 h heart rate
(beats/min)
85.0  11.4 87.9  10.0 88.6  12.9 85.4  12.3 .28 .72 .051
[71-111] [69-105] [63-122] [66-110]
n = 19 n = 19 n = 20 n = 18
Pulse wave velocity (m/s) 6.1  0.8 5.9  0.8 5.7  0.7 5.7  1.0 .10 .25 .007*
[4.9-7.3] [4.9-7.3] [4.7-7.4] [4.7-7.9]
n = 18 n = 18 n = 17 n = 17
24 h systolic blood pressure (mm Hg) 131.6  13.7 126.6  12.4 123.4  10.6 123.5  10.5 .034* .07 .08
[111-155] [105-153] [109-154] [105-143]
n = 16 n = 16 n = 17 n = 17
24 h diastolic blood pressure (mm Hg) 81.4  11.1 78.73  10.1 76.5  9.0 76.9  8.6 .26 .31 .13
[64-102] [62-97] [64-93] [63-96]
n = 16 n = 16 n = 17 n = 17
Visceral adipose
tissue (kg)
2.2  1.1 2.1  1.0 2.0  1.2 1.9  1.1 .29 .56 .71
[1.1-4.4] [1.0-4.5] [0.6-4.6] [0.5-4.1]
n = 15 n = 15 n = 15 n = 15
Body fat mass (%) 47.0  5.5 47.0  5.4 46.9  6.8 45.7  7.2 .30 .62 .36
[37.6-55.6] [37.7-55.3] [34.2-56.9] [32.9-55.1]
n = 19 n = 19
Muscle-mass (kg) 59.9  11.7 59.2  12.5 57.4  7.5 56.4  8.2 .08 .42 .81
[42.3-83] [41.4-83] [44.2-70.4] [45.8-72.1]
n = 20 n = 19
Android-to-gynoid
fat mass ratio
1.21  0.16 1.21  0.18 1.23  0.23 1.22  0.26 .70 .82 .58
[0.99-1.61] [0.95-1.58] [0.92-1.64] [0.9-1.81]
n = 19 n = 19 n = 18 n = 18
Abbreviation: BMI, body mass index.
Mean, standard deviation (SD) and range (in square brackets) are presented as mean  SD (min-max) in the table. “n” is provided when the number of
validated and/or obtained data points of a variable was <20. P values were analysed using repeated measures analysis of variance and signiﬁcant group
differences are indicated by asterisks (*). Columns represent effects of Time, Group and Time × Group interaction (treatment).
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of saxenda is recommended if body weight is not reduced by 5%
within the ﬁrst 12 weeks.33 This suggests that exenatide once-weekly
might also be more effective in higher doses in treating obesity;
however, if treatment is effective, weight loss would be expected in
the early phase of treatment. Here we used exenatide off-label; thus,
regulatory and ethical considerations prevented us from using higher
doses. Our results do not support use of exenatide once-weekly in
cases of antipsychotic-associated obesity; however, we cannot
exclude that weight loss might have been induced with more than
2 mg exenatide per week, or if treatment exceeded 3 months. Varia-
bility in the groups of 3.3 kg (exenatide) vs 4.4 kg (placebo) observed
on primary endpoint was larger than our a priori expectation of
2.5 kg. This larger variability may reﬂect a bias of different degrees
of motivation to achieve weight loss through diet and/or physical
exercise in the 2 groups. As we did not systematically assess diet and
physical exercise, theoretical between-group differences regarding
these factors could have inﬂuenced our ﬁndings.
In contrast to prior studies of GLP-1RAs, all patients in this study
were treated with antipsychotics. Although antipsychotics represent
complex pharmacology affecting multiple receptor systems (eg sero-
tonergic, histaminergic and cholinergic receptors) all antipsychotics
share afﬁnity for the dopamine D2 receptor.
8 Therefore, the absence
of effect of exenatide on body weight in our patients could suggest
that the body weight-lowering effect of GLP-1RAs may interact with
dopaminergic signaling. Because of the known inﬂuence of dopamin-
ergic signaling on appetite regulation in the brain reward system, we
TABLE 4 Incidences of adverse events reported in the 2 groups
during 3 months of treatment
Exenatide
(n = 23)
Placebo
(n = 22)
P
value
Nausea 30.4% (n = 7) 18.2% (n = 4) .34
Diarrhea 21.7% (n = 5) 0% (n = 0) .02*
Vomiting 4.3% (n = 1) 4.5% (n = 1) .97
Injection site
erythema
0% (n = 0) 4.5% (n = 1) .30
Fatigue 17.4% (n = 4) 0% (n = 0) .04*
Pneumonia 4.3% (n = 1) 9.1% (n = 2) .52
Debut of type
2 diabetes
0% (n = 0) 4.5% (n = 1) .30
Hospital admission 8.6% (n = 2) 13.6% (n = 4) .58
Psychiatric symptoms 17.4% (n = 4) 4.5 % (n = 1) .17
Psychiatric admission 13% ( n = 3) 0 % (n = 0) .16
Columns show frequencies of reported adverse events in percentage and
the number (n) of events for all enrolled patients (intention-to-treat princi-
ple) for both groups. Pearson’s Chi2 analyses were performed and signiﬁ-
cant group differences are indicated by asterisks (*).
TABLE 3 Biochemical fasting blood values
Exenatide (n = 20) Placebo (n = 20)
Time Group Time × Group
Baseline End-of-trial Baseline End-of-trial P value P value P value
HbA1c (mmol/mol) 33.3  3.3 36.2  3.4 34.7  4.8 39.15  13.4 .002* .33 .53
[28-40] [28-42] [25-47] [28-93]
Fasting plasma glucose
(mmol/L)
5.1  0.3 5.8  0.6 5.3  0.5 6.1  1.6 .001* .27 .60
[4.2-5.9] [5.0-7.4] [4.5-6.4] [4.9-12.4)
Plasma exenatide (pmol/L) 3.4  10.5 84.9  29.6 0.0  0 1.1  3.2 .002* <.001* .002*
[0-40] [65-147] [0-0] [0-11]
n = 17 n = 7 n = 18 n = 20
Anti-exenatide antibody
binding (%)
3.75  13.1 17.8  19.1 0.0  0.0 0.0  0.0 .004* <.001* .004*
[0-58] [0-50] [0-0] [0-0]
Plasma glucagon (pmol/L) 10.1  4.8 10.5  5.0 9.1  3.8 9.1  4.1 .24 .56 .38
[3-21] [1-23] [2-14] [2-18]
Triglyceride (mmol/L) 1.5  0.7 2.4  1.0 1.4  0.8 2.1  1.1 <.001* .46 .21
[0.6-3.2] [0.9-4.5] [0.4-3.1] [0.8-4.3]
Total cholesterol, (mmol/L) 4.5  1.0 5.2  1.1 4.2  0.7 5.0  0.9 <.001* .46 .47
[2.6-7.0] [3.1-7.7] [2.5-5.1] [3.2-6.9]
LDL cholesterol (mmol/L) 2.6  0.9 3.3  0.9 2.4  0.5 3.1  0.7 <.001* .46 .56
[0.7-4.4] [1.1-5.2] [0.9-3.0] [1.2-4.7]
VLDL cholesterol (mmol/L) 0.7  0.3 1.1  0.5 0.7  0.4 1.0  0.5 <.001* .48 .17
[0.3-1.4] [0.4-2.0] [0.2-1.4] [0.4-1.9]
HDL cholesterol (mmol/L) 0.9  0.2 1.1  0.2 1.0  0.3 1.1  0.3 <.001* .47 .46
[0.6-1.39] [0.69-1.6] [0.6-1.5] [0.7-1.8]
Abbreviations: HbA1c, hemoglobin A1c (<42 mmol/mol indicates normoglycemia; 42-47 mmol/mol indicates prediabetes and >48 mmol/mol indicates
diabetes); HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein.
Mean, standard deviation (SD) and range (in square brackets) are presented as: mean  SD (min-max in the table. “n” is provided when the number of
validated and/or obtained data points of a variable was <20. P values were analysed using repeated measures analysis of variance, and signiﬁcant group
differences are indicated by asterisks (*). Columns represent effects of Time, Group and Time × Group interaction (treatment).
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speculate that the observed GLP-1RA resistance (ie no weight loss) in
our antipsychotic-treated patients is associated with the central
(cerebral) effects of GLP-1.12 Supporting this notion, a recent study
showed that GLP-1R activation increased dopamine-turnover in the
amygdala, and that food-related reward, as well as the anorexic effect
of GLP-1, were associated with dopamine D2 receptor signaling.
34
However, we cannot rule out that blockade of other receptor sys-
tems (eg cholinergic,35 histaminergic36 and serotonergic37) also inter-
feres with the body weight-lowering effect of GLP-1RAs.
Corresponding to the modest reductions in body weight, we
found no effect of exenatide on waist and hip circumference, body
composition or muscle and fat tissue distribution. In contrast to a
GLP-1RA study in non-diabetic obese patients,38 we found unex-
pected signiﬁcant increases in HbA1c, fasting plasma glucose and
lipids after 3 months; however, parallel increases in these parameters
were also observed in the placebo group. This could indicate that
these metabolic parameters in antipsychotic-treated patients may not
be as responsive to weight loss as would be expected in the back-
ground population.39 In contrast, a study using exenatide twice-daily
and once-weekly in patients with type 2 diabetes found a signiﬁcant
lowering of HbA1c, regardless of weight loss.30
In accordance with previous observations in non-psychiatric
populations, we found that exenatide signiﬁcantly lowered systolic
blood pressure (Table 2).30 Moreover, exenatide signiﬁcantly lowered
pulse wave velocity indicative of reduced arterial stiffness, which
may be part of the physiological mechanisms behind GLP-1RA-
induced blood pressure reduction. The values of PWV observed in
this study are numerically lower than reported reference values cor-
rected for age and blood pressure.40,41 However, Mobil-O-Graph
appears to obtain PWV values, which are slightly lower than the
SphygmoCor measurements.26
The signiﬁcant changes in systolic blood pressure after exenatide
treatment were similar to those observed in non-psychiatric patients,
suggesting that the patients had received adequate doses of the drug,
and that the “peripheral” effect of exenatide was retained. Post hoc
correction for smoking status did not signiﬁcantly change results on
primary outcome or secondary outcomes and, to our knowledge,
smoking has not been shown to counteract the effect of GLP-1RA
treatment.
At end-of-trial, exenatide was detected in plasma in the exenatide
group, conﬁrming that trial medication was active and was adminis-
tered according to protocol. According to previous pharmacokinetic
studies on exenatide once-weekly, steady-state levels are reached
within 6-7 weeks of treatment.42 Also, the absolute mean levels
(84.9 pmol/L) are similar to those reported in previous studies of
exenatide once-weekly in non-psychiatric patients.43 As could be
expected from a previous study,42 13 out of 20 patients in the exena-
tide group developed anti-exenatide antibodies at end-of-trial
compared to none in the placebo group, but the presence of anti-
exenatide antibody did not alter our results.42
Methodological strengths of the current study include the rando-
mized, placebo-controlled, double-blinded trial design, with weight loss
as the primary outcome. We used a standard antidiabetic, ﬁxed dose
of 2 mg exenatide once-weekly, previously shown to result in weight
loss in obese patients with type 2 diabetes, as well as in obese non-
diabetic subjects. The once-weekly administration by trial personnel
ensured full medication compliance, which was further veriﬁed by
plasma measurements of exenatide, and the home visits contributed to
optimizing trial adherence as reﬂected in a low attrition rate of 11%30
Exenatide was well-tolerated and only diarrhea (P = .02) and fatigue
(P = .04) were more commonly reported in the exenatide group
(Table 4). In comparison with GLP-1RA studies in diabetic and obese
non-psychiatric patients, the exenatide group in the present study
reported fewer gastrointestinal side effects overall. It is known that
dopamine D2 receptor antagonism promotes an anti-emetic effect,
44
(eg olanzapine has proven efﬁcacy to reduce chemotherapy-induced
nausea).45 Possibly, the anti-emesis of antipsychotics resulted in fewer
gastrointestinal side effects than would be expected.
We aimed to conduct a proof-of-concept trial, and we intention-
ally included a naturalistic trial population, as reﬂected in the included
patients’ broad medication proﬁles. We cannot exclude that sub-
groups of obese antipsychotic-treated patients, eg patients treated
with monotherapy using aripiprazole, a partial dopamine D2 agonist,
or with antipsychotics with relatively low dopaminergic afﬁnity
(eg quetiapine, olanzapine or clozapine) may beneﬁt from GLP-1RA
treatment. Moreover, we cannot exclude that other GLP-1RAs
(eg liraglutide) or studies of longer treatment duration will show posi-
tive effects.
5 | CONCLUSIONS
Three months of treatment with the GLP-1RA, exenatide once-
weekly, had no placebo-corrected effect on body weight in our
obese, antipsychotic-treated patients with schizophrenia. Because
antipsychotics have dopamine D2-antagonism in common, our results
could suggest that the body weight-lowering effect of GLP-1RAs
may involve dopaminergic signaling. Obesity and cardiovascular
health remain critical public healthcare challenges in patients treated
with antipsychotics, and the lack of efﬁcient, long-term treatment
regimens, encourage future attempts to prevent weight-gain when
initiating antipsychotic treatment.
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